Annals of Surgical Oncology

, Volume 16, Issue 5, pp 1337–1343

Feasibility and Efficacy of Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy Combined with Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

  • Berrin Pehlivan
  • Francois Luthi
  • Oscar Matzinger
  • Michael Betz
  • Daniela Dragusanu
  • Shelley Bulling
  • Luc Bron
  • Philippe Pasche
  • Walter Seelentag
  • René O. Mirimanoff
  • Abderrahim Zouhair
  • Mahmut Ozsahin
Head and Neck Oncology

DOI: 10.1245/s10434-009-0426-4

Cite this article as:
Pehlivan, B., Luthi, F., Matzinger, O. et al. Ann Surg Oncol (2009) 16: 1337. doi:10.1245/s10434-009-0426-4

Background

The aim of this study was to assess feasibility and efficacy of weekly concomitant boost accelerated postoperative radiation therapy (PORT) with concomitant chemotherapy (CT) in patients with locally advanced head and neck cancer (LAHNC).

Methods and Materials

Conformal or intensity-modulated 66-Gy RT was performed in 5.5 weeks in 40 patients. Cisplatin was given at days 1, 22, and 43. Median follow-up was 36 months.

Results and Discussion

Grade 3 mucositis, dysphagia, and erythema was observed in ten (25%), nine (23%), and six (13%) patients, respectively. Grade 3 or more anemia was observed in two (6%) patients, and leukopenia in five (13%) patients. No grade 3 or 4 thrombocytopenia was observed. Grade 3 nephrotoxicity was observed in one patient (3%). No treatment-related mortality was observed. Grade 2 or more xerostomia and edema were observed in ten (25%) and one (3%) patient, respectively. Locoregional relapse occurred in eight patients, and seven patients developed distant metastases. Median time to locoregional relapse was 6 months. Three-year overall, disease-free survival, and locoregional control rates were 63%, 62%, and 81%, respectively. Multivariate analysis revealed that the only prognostic factor was nodal status.

Conclusion

Reducing overall treatment time using accelerated PORT/CT by weekly concomitant boost (six fractions per week) combined with concomitant cisplatin CT is easily feasible with acceptable morbidity.

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Berrin Pehlivan
    • 1
  • Francois Luthi
    • 2
  • Oscar Matzinger
    • 1
  • Michael Betz
    • 1
  • Daniela Dragusanu
    • 1
  • Shelley Bulling
    • 1
  • Luc Bron
    • 3
  • Philippe Pasche
    • 3
  • Walter Seelentag
    • 4
  • René O. Mirimanoff
    • 1
  • Abderrahim Zouhair
    • 1
  • Mahmut Ozsahin
    • 1
  1. 1.Department of Radiation OncologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  2. 2.Department of Medical OncologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  3. 3.Department of OtorhinolaryngologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  4. 4.Department of PathologyUniversity Hospital Center, University of LausanneLausanneSwitzerland